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Introduction
It is expected that human gene therapy will often depend upon the delivery of highly specific and stable anti-sense agents to their desired site of action, away from sites of potential toxicity. This requires an understanding of the mechanisms of cellular uptake and sub-cellular trafficking of molecules, which can regulate gene expression. Peptide nucleic acids (PNAs) are novel, synthetic DNAlike molecules in which the chains of pyrimidine and purine bases are linked by an aminoethyl (pseudopeptide) backbone. 1 This structure confers two important properties on the molecule: (1) highly specific hybridisation and affinity to complementary DNA and RNA; 2 and (2) resistance to nuclease and protease attack. 3 As a result, PNAs have been shown to be important in various diagnostic and therapeutic applications. 1, 4 Despite their enormous potential as therapeutic agents, reports of poor cellular uptake, due to their low phospholipid permeability, dampened the initial enthusiasm. [5] [6] [7] [8] However, early studies on PNA import were limited to a small number of different cell lines and import conditions. In addition, it is well recognised that oligodeoxynucleotide uptake can differ markedly between different cell types. For example, muscle cells are particularly amenable to DNA and modified DNA uptake, possibly because of the transverse tubule system and specific cell surface receptors. 9 Whilst PNAs have great potential as anti-sense agents to regulate nuclear gene expression, we are also very interested in their efficacy as anti-genomic therapeutic agents for disorders of the mitochondrial genome. MtDNA defects cause a diverse group of progressive diseases. 10 At present there is no effective treatment for these disorders, 11 which often result in severe disability and premature death. 12 Each human cell contains between 1000 and 100 000 copies of mtDNA which encodes 13 essential polypeptides that form part of the mitochondrial respiratory chain. 13 The majority of patients who harbour pathogenic mtDNA defects have a mixture of mutated and wild-type mtDNA (heteroplasmy). On a cellular level, the phenotypic defect is only expressed when the percentage of mutated mtDNA exceeds a critical threshold, 14 and the clinical features of mtDNA disease are intimately dependent upon the ratio of mutated and wild-type mtDNA in vivo. 15 Unlike nuclear DNA, mtDNA is continuously being copied and degraded with a half-life estimated to be between 0.7 and 30 days in rat tissue. 16 By specifically inhibiting the turnover of mutated mtDNA, it is theoretically possible to correct the biochemical defect, prevent clinical progression and potentially reverse some of the pathological features of mtDNA disease. 17 We have shown that sequence-specific PNAs selectively inhibit the replication of mutated mtDNA in vitro, 18 but future applicability of this approach is dependent upon the development of a mutation-specific antimtDNA agent which can be targeted into mitochondria in vivo.
Because of the potential importance of PNAs in the gene therapy of both nuclear and mtDNA disease we have studied their uptake in a variety of different cell lines and under different conditions. We show that biotinylated PNAs are readily internalised by a variety of cell lines. A further hurdle in the development of mitochondrial gene therapy is the delivery of the antigenomic agent into double-membrane bound cytoplasmic organelles. 17 We report the successful import of PNAs into isolated mitochondria upon conjugation of the biotinylated PNA molecule to a mitochondrial targeting presequence. Finally, we also report that addition of this presequence successfully targets the PNA to mitochondria in human myoblasts.
Results
PNAs are internalised by cultured cell lines We studied the uptake of an 11-mer biotin-labelled PNA. This PNA (identical to PNA-MERRF in Ref. 18 ) was chosen as we have previously shown that it can selectively inhibit replication of mutated mtDNA in vitro. Cell lines were exposed to 20 m biotinylated PNA for 4 h. After fixation, the cells were labelled with streptavidinfluorescein before immediate image collection by confocal fluorescence microscopy. For human fibroblasts, HeLa, HepG2 and SY5Y (Figure 1 ), the mean intracellular fluorescence relative to background (MIF/B) was significantly greater in the PNA-exposed cells compared with controls (Table 1) , consistent with the import seen previously with human myoblasts and repeated here (Ref. 18 , Table 1 and Figure 2 ). The MIF/B for the biotintreated myoblasts was not significantly greater than control values (MIF/B biotin 0.85, s.d. 0.12, n = 16, Figure 2 ), confirming that the increase seen in the biotinylated PNA exposed cells was due to PNA uptake and not free biotin following degradation of the biotinylated PNA molecule. Despite numerous attempts, the NT2 and IMR 32 cell lines did not adhere to the slide during fixation and labelling.
Three distinct phases following the uptake of PNA into human myoblasts A time course revealed three distinct phases following biotinylated PNA uptake into human myoblasts. Within 30 min of exposure, punctate staining was apparent within the cytoplasm (Figure 2c ), which increased up to 4 h exposure (Figure 2d ). Between 6 and 8 h exposure, the punctate fluorescence decreased, the cytoplasm became more diffusely fluorescent and there was a low level signal in the nucleus (Figure 2e ). In the third phase, after 8-12 h, intranuclear fluorescence was more intense and was still visible 24 h after exposure (Figure 2f) . A similar triphasic pattern was observed with a biotinylated oligodeoxynucleotide, consistent with PNA and DNA molecules sharing a similar import pathway (data not shown). We saw little residual punctate staining in myoblasts exposed to 20 m biotinylated PNA for greater than 12 h. Pulsing the myoblasts with 20 m biotinylated PNA for 15 min and 30 min led to a significant reduction in the amount of punctate fluorescence 6 h later, but the effects of a 1 h pulse were indistinguishable from myoblasts exposed continuously for 6 h (data not shown).
PNA uptake into human myoblasts is concentration dependent The intracellular fluorescence in cells exposed to 1 m biotinylated PNA was indistinguishable from control values ( Table 2 ), consistent with a threshold level for the detection of uptake. Intracellular fluorescence was greater in myoblasts exposed to 10 m biotinylated PNA in comparison to those exposed to biotinylated-5 m PNA. Increasing the concentration to 20 m did not result in a significant increase in intracellular fluorescence after 4 h exposure, consistent with saturation of the PNA uptake mechanism in human myoblasts.
Intracellular targeting of peptide nucleic acids
As shown in the previous sections, biotinylated PNAs are internalised by human myoblasts in culture. Our main aim, however, is to determine whether PNAs can be effective agents in treating patients with defects of the mitochondrial genome. Once internalised, it is therefore of fundamental importance to target these molecules to mitochondria and to demonstrate import into the mitochondrial matrix. In order to achieve this, we synthesised the identical biotinylated PNA attached to the C-terminus of a known mitochondrial targeting presequence which directs the import of the nucleus-encoded cytochrome c oxidase (COX) subunit VIII into mitochondria. 19 Quantification of the cellular internalisation of peptide-PNA conjugates One major advantage of the biotinylated peptide-PNA conjugate over the biotinylated PNA alone is that the conjugate can be resolved by denaturing gel electrophoresis, migrating on SDS-PAGE as a function of its molecular weight. The biotinylated conjugate can then be visualised with 35 S-radiolabeled streptavidin following Western transfer. To quantify internalisation, human myoblasts were bathed in culture media containing varying concentrations of the biotinylated conjugate for zero or 180 min. Cells were washed and several aliquots were trypsinized to remove adventitiously bound conjugate before subjecting cell lysates to denaturing gel electrophoresis as detailed in Materials and methods. Quantification was made by comparing the signals from the internalisation experiments ( Figure 3a ) against a standard curve (Figure 3b and c). As shown in Figure 3 , approximately 5000 myoblasts bathed in 2 m biotinylated conjugate were able to internalise 11.5 pmols in 3 h. This represented an import of approximately 6% of the biotinylated conjugate in the culture media. Internalisation was not limited by even the highest (5 m) concentration of biotinylated conjugate.
PNA import into isolated mitochondria
Having demonstrated that the biotinylated peptide-PNA conjugate can be internalised, we then wished to determine whether the conjugate could be targeted to and imported by mitochondria. Rat liver mitochondria were first tested for their import-competence by demonstrating import of a 35 S-methionine-labeled pSu9-DHFR chimaeric preprotein. Mitochondrial import of this chimaeric protein has been well characterised. 20 It contains the first 69 residues of N. crassa F o -ATP synthase subunit 9, fused Nterminal to murine dihydrofolate reductase. When mitochondria were incubated with pSu9-DHFR, the preprotein was cleaved, liberating the mature form (22 kDa) which was resistant to proteolysis by added proteinase K (Figure 4a ). No preprotein cleavage and no proteaseresistant material were observed when the membrane potential was dissipated by addition of the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP). The uptake of biotinylated peptide-PNA conjugate was studied in parallel experiments ( Figure 4b ). As discussed in the previous section, experiments with biotinylated PNA molecules that do not carry a peptide presequence revealed that these small, uncharged molecules do not enter polyacrylamide gels, even in the presence of SDS. To visualise import, it was therefore necessary to prevent cleavage of the charged peptide from the conjugate, as the biotinylated peptide-PNA conjugate could be freely resolved by gel electrophoresis. Cleavage of the presequence in these experiments was prevented by the addition of 1,10-phenanthrolene and EDTA which inhibit the metal ion-dependent matrix processing peptidase, MPP. Identical import experiments were performed with mitoplasts, in which the outer mitochondrial membrane was selectively permeabilised with digitonin, thereby allowing proteinase K access to the inter-membrane space. These experiments gave essentially the same results as those with intact mitochondria in that a proteinase-resistant peptide-PNA derivative was detectable after incubation with mitoplasts ( Figure 4c , lane 2), consistent with the biotinylated peptide-PNA conjugate being imported into the matrix. The addition of CCCP to the import reaction inhibited the import of the peptide-PNA conjugate into mitoplasts (Figure 4c, lane 3) . Taken together, these in vitro studies demonstrate the membrane potential-dependent translocation of the biotinylated peptide-PNA conjugate into the mitochondrial matrix.
Targeting PNA to mitochondria in cultured human myoblasts We compared the uptake of the biotinylated peptide-PNA conjugate to the uptake of the non-conjugated bioti- 
proteinase K degraded all non-specifically bound peptide-PNA conjugate (lane 4). (c) Import of biotinylated peptide-PNA conjugate into rat liver mitoplasts. Import of conjugate into the mitochondrial matrix was confirmed by performing identical import reactions in mitoplasts prepared by digitonin treatment of intact rat liver mitochondria (see Materials and methods). Treatment of the import reaction with proteinase K revealed a proteinase-resistant, imported conjugate (lane 2). This import was sensitive to the addition of CCCP (+PK; lane 3).
nylated PNA by confocal fluorescence microscopy ( Figure 5 ). Mitochondria were identified by the red fluorescent signal from the dye MitoTracker Red CMXRos. 21 Both the biotinylated PNA and biotinylated peptide-PNA were identified by the blue-green fluorescent signal of streptavidin-fluorescein. Mean blue-green fluorescence pixel intensity for the nuclear and mitochondrial compartments were expressed relative to background and statistical analyses were performed as described previously. For myoblasts treated with 20 m biotinylated PNA for 8 h (Figure 5c 
Discussion
We have shown that biotinylated PNAs are readily imported from culture medium by a number of different cell lines. Internalisation by myoblasts followed three distinct phases: punctate, diffuse cytosolic and then nuclear localisation. Why have other investigators failed to show PNA uptake into cells? The demonstration of uptake is dependent upon the detection methods employed. The uptake of DNA 22 and PNA 23 are cell-type specific and concentration dependent. Different investigators have studied PNA uptake at lower concentrations and not in the cell types that we have studied. 7 Despite a sensitive semi-quantitative detection method, relatively high concentrations of PNA (Ͼ1 m) were needed to demonstrate uptake in our study. PNA uptake has been shown to occur in transformed and immortalised cell lines, 24 probably by fluid-phase endocytosis. Unlike the fluorochrome tagged PNAs used by Bonham and colleagues, 7 these investigators radiolabelled the PNA with 14 Cformaldehyde. 24 It is therefore possible that these different labelling techniques influence the rate and pattern of PNA uptake in these studies. For example, extracellularly delivered fluorescent-labelled PNA remained within cytoplasmic endosomes, and did not localise within the nucleus. 7 By contrast, nuclear uptake was clearly demonstrated with the radiolabelled PNA molecules 24 and with both biotinylated PNA and biotinylated peptide-PNA in our study.
Mitochondrial targeting and import
Mammalian mitochondria, unlike many plant, yeast and protozoan counterparts, do not need to import nucleic acids for efficient intra-mitochondrial protein translation. There is some evidence to suggest that the RNA moiety of a ribonucleoprotein possibly involved in maturing RNA primers for mtDNA replication may need to be imported, but the mitochondrial location of this RNP is still disputed. 25, 26 Schon and colleagues have recently reported that a 5S ribosomal RNA may be imported, but its function has yet to be determined. 27 It is therefore possible that mammalian mitochondria do not possess an efficient import mechanism for nucleic acids. Vestweber and Schatz, 28 however, were able to demonstrate that by subjecting import-competent, isolated mitochondria to DNA-conjugated mitochondrial precursor proteins, the DNA became nuclease or phosphodiesterase resistant, consistent with the mitochondria importing nucleic acids via the general protein import pathway. A similar observation was more recently reported by Seibel et al, 29 although their experiments involved a less direct analysis of the putatively imported DNA moiety. Our in vitro studies with isolated rat liver mitochondria now show that biotinylated PNAs can also be delivered across an intact mitochondrial membrane into the matrix compartment by the addition of a mitochondrial targeting peptide. The import of the biotinylated PNA-COX VIII conjugate required nucleoside triphosphates and an intact inner mitochondrial membrane potential. We have now extended these in vitro observations by confirming mitochondrial localisation of the peptide-PNA conjugate within intact cells by confocal fluorescence microscopy. The resolution of this technique was not sufficient to determine the exact intra-mitochondrial localisation of the PNA, but taken together with our in vitro import assays, it is reasonable to suggest that the PNA conjugate was imported to the mitochondrial matrix. Although it is not possible to comment on the degree of processing of the biotinylated peptide-PNA conjugate, we have shown that cleavage is not necessary for the sequence-specific inhibition of mutated mtDNA replication (Taylor et al, unpublished observations).
In conclusion, we have shown that biotinylated PNA molecules are readily internalised by various cell types. Ultimately the PNA localises to the nucleus, but conjugating the molecule with a mitochondrial-specific targeting sequence directs at least a subset of the molecules to mitochondria. Although addition of the presequence facilitated mitochondrial targeting and import, this was not entirely efficient, as a fraction of the molecules were still localised to the nucleus. In our studies, however, we did not detect any cytotoxicity in cells grown for 10 days in 20 m biotinylated PNA.
When coupled with our in vitro studies, 18 these observations highlight the importance of PNAs as potential anti-sense agents. Although there are many uncertainties surrounding the precise mechanisms of uptake and intracellular trafficking, the evidence presented in this study supports the use of PNAs as potential tools for nuclear and mitochondrial gene therapy.
Materials and methods
Synthesis of PNA and peptide-PNA conjugate The biotinylated peptide nucleic acid (PNA) was synthesised by PerSeptive Biosystems (Framingham, MA, USA) from Fmoc expedite monomers. The full construct Bio-O-O-GTTGGCTCTCT-O-Lys-CONH2 was HPLC purified and the correct synthesis was confirmed by MALDI-TOF. Synthesis of the peptide-PNA conjugate was performed by using standard Fmoc protection chemistry with TBTU as activator (ALTA Biosystems, University of Birmingham, UK). The PNA monomers and the Fmoc amino acids were purchased from PerSeptive Biosystems. The biotinyl-lysine and the PNA component were synthesised manually on a Biotech Instruments BT7600. Resin was removed and added to the reactor column of a PerSeptive Biosystems Pioneer instrument for the automated addition of the peptide. Cleavage from the solid phase was achieved with a mix of trifluoroacetic acid:water:ethane dithiol (95:2:5:2.5). The full conjugate, containing the PNA with an identical sequence to the non-conjugated PNA, was MSVLTPLLLRGLTGSARR LPVPRAKIHSL-PNA-Lys(biotin). This was HPLC purified and correct synthesis confirmed by N-terminal sequence analysis.
Cell culture and import conditions
Human cell lines were grown in multi-chamber microscope slide wells until 70% confluent (myoblasts, fibroblasts, Ntera 2, IMR32, HeLa, and HepG2 cell lines). Muscle cells were grown in Hams F10 medium (Gibco BRL) supplemented with 20% (v:v) foetal calf serum (FCS) and 1% (v:v) chick embryo extract. Fibroblast explant cultures were grown in Earle's modified Eagle's medium (EMEM, Sigma-Aldrich, Poole, UK) supplemented with 10% (v:v) FCS. Human Ntera 2 cell lines were grown in EMEM supplemented with 10% FCS, 1% (w:v) non-essential amino acids, and 1% (w:v) l-glutamine. HeLa cells were grown in EMEM supplemented with 5% (v:v) FCS and 2 mm lglutamine. Hep G2 cells were grown in EMEM supplemented with 10% (v:v) FCS, 2 mm l-glutamine, and non-essential amino acids. Twelve hours before transfection the cells were transferred to serum-free medium. Various concentrations of the biotin-labelled 11-mer PNA, a 5Ј biotin-labelled 14-mer oligodeoxynucleotide, and the biotin-labelled peptide-PNA construct were added to the medium in concentrations ranging from 1 to 20 m. The cells were returned to a 5% CO 2 incubator at 37°C for the required time period.
Cell fixation, fluorescent labelling and confocal microscopy After a variable time period, the cells were rinsed for 3 min on three occasions in phosphate buffered saline (pH 7.4) before fixation with freshly prepared 2.5% paraformaldehyde at 4°C for 15 min. Cells were then permeabilised with 0.5% (v/v) Triton X-100 in 2.5% paraformaldehyde for a further 15 min at 4°C before three additional 3-min PBS rinses at room temperature. Cells were then exposed to streptavidin-fluorescein (1:50, Boehringer Mannheim, Lewes, UK) for 1 h. Excess label was removed with three further PBS rinses before embedding in glycerol/PBS (1:2 v/v). Images were collected immediately on a BioRad-MRC 600 confocal microscope with fixed laser and photomultiplier parameters (Kallman filter factor 5). Control chambers were prepared in exactly the same way in an adjacent chamber on the microscope slide. For the mitochondrial uptake studies, the mitochondrial-specific fluorescent dye dihydrotetramethylrosamine 20 (Mito Tracker, Molecular Probes, Eugene, OR, USA) was added to the culture medium to give a final concentration of 2 m, 45 min before fixation.
Image and statistical analysis Digital image analysis was performed (COMOS). Semiquantitative analysis of mean pixel intensity within the cells and subcompartments of the cells were measured from randomly chosen areas. The mean pixel intensity for each subcellular compartment was expressed relative to the background levels (mean fluorescence above background). Different values were compared by twosample t tests and analysis of variance when appropriate.
Quantification of internalised peptide-PNA conjugate
Approximately 5-10 000 human myoblasts were seeded into the wells of a 96-well microtitre tray. After 24 h, varying concentrations of conjugate were added to 100 l serum-free medium and cells were either immediately washed or left for 3 h to internalise the biotinylated conjugate. After washing in PBS, some aliquots were trypsinized (5 g trypsin 15 min 0°C) before all aliquots were lysed by sample loading buffer and separated through a 16.5% tris-tricine gel. Separated proteins were transferred (200 mA for 16 h) on to PVDF membranes (Immobilon-PSQ, Millipore, Watford, UK), and the biotinylated peptide-PNA conjugate detected following incubation in 
Isolation of rat liver mitochondria
Rat liver mitochondria were prepared as previously described 30 and the protein concentration 31 adjusted to 20 mg/ml. Spectrophotometric assay of the mitochondrial matrix marker citrate synthase in the presence and absence of Triton X-100
32 was performed to demonstrate the intactness (92-95%) of mitochondrial membranes.
In vitro mitochondrial preprotein import
The ability of isolated rat liver mitochondria to import precursor proteins was routinely confirmed using the fusion protein pSu9-DHFR. 22 The fusion protein was synthesised in rabbit reticulocyte lysate (Promega, Southampton, UK) using 35 S-methionine (ICN Radiochemicals, Basingstoke, UK; 1000 Ci/mmol), and analysed by SDS-polyacrylamide gel electrophoresis (PAGE) and autoradiography. Import reactions (100 l total volume) were performed using 200 g mitochondrial protein in a buffer (220 mm mannitol, 70 mm sucrose, 10 mm Hepes-KOH, pH 7.4, 1 mm MgCl 2 , 1 mm DTT, 1 mm EDTA) supplemented with 1 mm ATP, 5 mm NADH, 20 mm sodium succinate, 0.1 mm GTP, 1.5 mm creatine phosphate and 15 g/ml creatine kinase. The import was initiated by the addition of 5 l of labelled pSu9-DHFR and incubated at 30°C for 60 min under conditions in which the inner membrane potential was either maintained or disrupted by the inclusion of 50 m carbonyl cyanide m-chlorophenylhydrazone (CCCP) in the import buffer. Proteinase resistance of the imported protein was assessed by incubating samples with 5 g proteinase K for 30 min on ice. The proteinase was inactivated by the addition of 1 mm phenylmethylsulfonyl fluoride, mitochondrial membranes washed in 1 ml of isolation medium and pelleted (13 000 g for 10 min). Mitochondrial pellets were resuspended in sample gel-loading buffer, and proteins analysed by SDS-PAGE and autoradiography.
In vitro import of peptide-PNA conjugate Isolated rat liver mitochondria were pre-incubated with 2 mm 1,10-phenanthroline and 5 mm EDTA for 15 min on ice before initiating import reactions by the addition of 200 pmol peptide-PNA conjugate. Imports were performed at 30°C for 60 min, again in the presence and absence of CCCP. Following proteinase K treatment (as detailed above), mitochondria were pelleted, solubilised and separated through 16.5% tris-tricine gels. Separated proteins were transferred (200 mA for 16 h) on to PVDF membranes, and the biotinylated peptide-PNA conjugate detected following incubation in 35 S-streptavidin by Phosphorimage analysis. Preincubation of mitochondrial fractions with 1,10-phenanthroline and EDTA inhibits the activity of the matrix MPP, thereby allowing the peptide-PNA conjugate to remain unprocessed and maintain its electrophoretic property. Proteinase treatment of the mitochondria after import allows the detection of proteinase-resistant, imported PNA molecules. To confirm the presence of the biotinylated peptide-PNA within the mitochondrial matrix compartment, similar import experiments were performed using mitoplasts prepared by treating mitochondrial aliquots with increasing amounts of digitonin for 15 min on ice. Those aliquots that had been treated with the highest amount of digitonin to result in the release of less than 5% of the total citrate synthase activity were deemed to be mitoplasts. Aliquots (200 g) were washed, pelleted (6000 g for 10 min), and import reactions performed as described above.
